Hikma Pharmaceuticals PLC (LON:HIK) Stock Has Average Price Target of GBX 2,085.83

Hikma Pharmaceuticals PLC (LON:HIK) has been given a consensus rating of “Buy” by the six research firms that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is GBX 2,085.83.

A number of brokerages have issued reports on HIK. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,025 price objective on shares of Hikma Pharmaceuticals in a research report on Friday, September 25th. Citigroup upped their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Berenberg Bank increased their target price on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research report on Tuesday, August 11th.

Hikma Pharmaceuticals Price Performance

Shares of Hikma Pharmaceuticals stock opened at GBX 1,715.29 on Friday. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. Hikma Pharmaceuticals has a twelve month low of GBX 1,187 and a twelve month high of GBX 1,865. The business has a 50-day moving average price of GBX 1,616.37 and a 200 day moving average price of GBX 1,503.22. The firm has a market cap of £3.55 billion, a PE ratio of 9.75, a P/E/G ratio of 2.38 and a beta of 0.65.

Insider Buying and Selling at Hikma Pharmaceuticals

In other news, insider Tobias Hestler acquired 7,500 shares of the business’s stock in a transaction on Monday, August 10th. The stock was bought at an average cost of GBX 1,648 per share, for a total transaction of £123,600. 22.26% of the stock is currently owned by company insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.